يحاول ذهب - حر
VFL Sciences announces cooperation with RocGene Technology
March 2025
|Bio Spectrum
Chennai-based VFL Sciences and RocGene Technology, based in China, have signed an agreement of cooperation wherein VFL Sciences will exclusively sell the entire range of products from RocGene in India.
-
This multiyear cooperation will enable both companies to explore the Indian market and devise strategies and road map to further strengthen their presence.
هذه القصة من طبعة March 2025 من Bio Spectrum.
اشترك في Magzter GOLD للوصول إلى آلاف القصص المتميزة المنسقة، وأكثر من 9000 مجلة وصحيفة.
هل أنت مشترك بالفعل؟ تسجيل الدخول
المزيد من القصص من Bio Spectrum
Bio Spectrum
Park Medi World buys KP Institute of Medical Sciences for Rs 245 Cr
Park Medi World Limited, North India's second largest chain of hospitals, has agreed to acquire KP Institute of Medical Sciences (KPIMS), in an all-cash transaction amounting to Rs 245 crore.
1 min
February 2026
Bio Spectrum
Decode Age raises Rs 14.48 Cr to advance longevity science and gut microbiome research
Bengaluru-based Decode Age, a longevity science organisation focused on ageing biology, biomarker research and gut microbiome science, has raised Rs 14.48 crore in its Pre Series A funding round led by Dr Krishna Prasad Chigurupati, Chairman and Managing Director, Granules India Limited.
1 min
February 2026
Bio Spectrum
Havih Envirosciences announces partnership with Andhra Pradesh
Havih Envirosciences, a subsidiary of Maxwell Biosciences, has announced a strategic partnership with the Government of Andhra Pradesh to establish advanced pharmaceutical research and production capabilities in the state.
1 min
February 2026
Bio Spectrum
Biofabri and Bharat Biotech ink technology transfer agreement to advance global access to MTBVAC
Biofabri, a global human vaccine development company that is part of Spain-based Zendal group, and Bharat Biotech International Limited (BBIL) in Hyderabad, a global leader in vaccine innovation and manufacturing, have announced the signing of a Technology Transfer Agreement.
1 min
February 2026
Bio Spectrum
Care ADHD expands global operations with first GCC in India
Care ADHD, one of the United Kingdom's fastest growing digital mental health companies and a key partner to the NHS, has announced the opening of its first Global Capability Centre (GCC) in India - Bengaluru.
1 min
February 2026
Bio Spectrum
PM launches Ayush Mark, setting global quality benchmarks for India's traditional medicine
In a historic and visionary move that marks a defining moment for India's traditional medicine ecosystem, Prime Minister (PM) Narendra Modi has launched the Ayush Mark, establishing a globally aligned quality certification framework for Ayush products and services.
1 min
February 2026
Bio Spectrum
US announces $50 B in awards to strengthen rural healthcare
The Centers for Medicare & Medicaid Services (CMS) has announced that all 50 states will receive awards under the Rural Health Transformation Program, a $50 billion initiative established under President Trump's Working Families Tax Cuts legislation (Public Law 119-21) to strengthen and modernise healthcare in rural communities across the country.
1 min
February 2026
Bio Spectrum
Novo Nordisk launches world's most prescribed GLP-1 drug Ozempic in India
Novo Nordisk, a global healthcare company, has announced the launch of Ozempic (injectable semaglutide) in India.
1 min
February 2026
Bio Spectrum
Vyome inches towards US FDA approval to enter $1B worth malignant fungating wound market
Vyome Holdings, Inc., a startup based both in the US & India, has announced the final results from an investigator-initiated Phase 2 proof of concept study of VT-1953 topical gel in people with malignant fungating wounds (MFW). VT-1953, a first-in-class immunomodulator for this indication, achieved both its primary & secondary endpoints.
1 min
February 2026
Bio Spectrum
Symbiotec Pharmalab files DRHP with SEBI for IPO aggregating upto Rs 2180 Cr
Indore-based Symbiotec Pharmalab, a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms-organic chemistry, biotechnology and complex injectables, has filed its Draft Red Herring Prospectus (DRHP) with market regulator Securities and Exchange Board of India (SEBI).
1 min
February 2026
Listen
Translate
Change font size